In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: Trends across multiple chemical series

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 1, 2008, Pages 355-359

  Nersesian, Diana L ^a   Black, Lawrence A ^a   Miller, Thomas R ^a   Vortherms, Timothy A ^a   Esbenshade, Timothy A ^a   Hancock, Arthur A ^a   Cowart, Marlon D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ADHD; Histamine H3; Imidazoles; Serotonin

Indexed keywords

2 METHYLPYRROLIDINE DERIVATIVE; HISTAMINE H3 RECEPTOR ANTAGONIST; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MOLECULAR WEIGHT; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; HISTAMINE H3 ANTAGONISTS; HUMANS; KINETICS; PYRROLIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37549005590     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.067     Document Type: Article

References (35)

1. Hill S.J., Ganellin C.R., Timmerman H., Schwartz J.-C., Shankley N.P., Young J.M., Schunack W., Levi R., and Haas H.L. Pharmacol. Rev. 49 (1997) 253
2. Arrang J.-M., Garbarg M., and Schwartz J.-C. Nature 302 (1983) 832
3. Leurs R., Blandina P., Tedford C., and Timmerman H. Trends Pharmacol. Sci. 19 (1998) 177
4. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., and Erlander M.G. Mol. Pharmacol. 55 (1999) 1101
5. Leurs R., Bakker R.A., Timmerman H., and de Esch I.J.P. Nat. Rev. Drug Discov. 4 (2005) 107
6. Stark H., Schlincher E., and Schunack W. Drugs Fut. 21 (1996) 507
7. Tozer M.J., and Kalindjian S.B. Exp. Opin. Ther. Patents (2000)
8. Bennani Y.L., Black L.A., Faghih R., Hancock A.A., and Decker M.W. Behav. Brain Res. 131 (2002) 151
9. Halpern M.T. Curr. Opin. Cent. Peripher, Nerv. Syst. Invest. Drugs 1 (1999) 524
10. Ali S.M., Tedford C.E., Gregory R., Handley M.K., Yates S.L., Hirth W.W., and Phillips J.G. J. Med. Chem. 42 (1999) 903
11. Fox, G. B.; Pan, J. G.; Esbenshade, T. A.; Switzerland, 2004; p 97.
12. Babier A.J., Berridge C., Dugovic C., Laposky A.D., Wilson S.J., Boggs J., Aluisio L., Lord B., Mazur C., Pudiak C.M., Langlois X., Xiao W., Apodaca R., Carruthers N.I., and Lovenberg T.W. Br. J. Pharmacol. 143 (2004) 649
13. Hancock A.A. Curr. Opin. Investig. Drugs 4 (2003) 1190
14. Hancock A.A., Bennani Y.L., Bush E.N., Esbenshade T.A., Faghih R., Fox G.B., Jacobson P., Knourek-Segal V., Krueger K.M., Nuss M.E., Pan J.B., Shapiro R., Witte D.G., and Yao B.B. Eur. J. Pharmacol. 487 (2004) 183
15. Malmolof K., Zaragoza F., Golozoubova V., Refsgaard H.H.F., Cremers T., Raun K., Wulff B.S., Johansen P.B., Westerink B., and Rimvall K. Int. J. Obesity 29 (2005) 1402
16. Celanire S., Wijtmans M., Talaga P., Leurs R., and de Esch I.J.P. Drug Discov. Today 10 (2005) 1613
17. Esbenshade T.A., Fox G.B., and Cowart M.D. Mol. Interventions 6 (2006) 77
18. Arrang J.M., Morisset S., Rouleau A., Gbahou F., Ligneau X., Tardivel-Lacombe J., Stark H., Schunack W., Ganellin C.R., and Schwartz J.-C. Int. Congr. Ser. 1249 (2003) 139
19. Stark H. Exp. Opin. Ther. Pat. 13 (2003) 851
20. Meier G., Apelt J., Reichert U., Grassman S., Ligneau X., Elz S., Leurquin F., Ganellin C.R., Schwartz J.-C., Schunack W., and Stark H. Eur. J. Pharmacol. Sci. 12 (2001) 249
21. Faghih R., Dwight W., Vasudevan A., Dinges J., Conner S.E., Esbenshade T.A., Bennani Y.L., and Hancock A.A. Bioorg. Med. Chem. Lett. 12 (2002) 3077
22. Apodaca R., Dvorak C.A., Xiao W., Barbier A.J., Boggs J.D., Wilson S.J., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 46 (2003) 3938
23. sbenshade T.A., Fox G.B., Krueger K.M., Miller T.R., Kang C.J., Denny L.I., Witte D.G., Yao B.B., Pan L., Wetter J., Marsh K., Bennani Y.L., Cowart M.D., Sullivan J.P., and Hancock A.A. J. Pharmacol. Exp. Ther. 313 (2005) 165
24. Fox G.B., Esbenshade T.A., Pan J.B., Radek R.J., Krueger K.M., Yao B.B., Browman K.E., Buckley M.J., Ballard M.E., Komater V.A., Miner H., Zhang M., Faghih R., Rueter L.E., Bitner R.S., Drescher K.U., Wetter J., Marsh K., Lemaire M., Porsolt R.D., Bennani Y.L., Sullivan J.P., Cowart M.D., Decker M.W., and Hancock A.A. J. Pharmacol. Exp. Ther. 313 (2005) 176
25. Veber D.F., Johnson S.R., Chen H.-Y., Smith B.R., Ward K.W., and Kopple K.D. J. Med. Chem. 45 (2002) 2615
26. Wenlock M.C., Austin R.P., Barton P., Davis A.M., and Leeson P.D. J. Med. Chem. 46 (2003) 1250
27. Cowart M., Faghih R., Curtis M.P., Gfesser G.A., Bennani Y.L., Black L.A., Pan L., Marsh K.C., Sullivan J.P., Esbenshade T.A., Fox G.B., and Hancock A.A. J. Med. Chem. 48 (2005) 38
28. Cowart M.D., Pratt J.K., Stewart A.O., Bennani Y.L., Esbenshade T.A., and Hancock A.A. Bioorg. Med. Chem. Lett. 14 (2004) 689
29. Black L.A., Nersesian D.L., Sharma P., Ku Y.-Y., Bennani Y.L., Marsh K.C., Miller T.R., Esbenshade T.A., Hancock A.A., and Cowart M.D. Bioorg. Med. Chem. Lett. 17 (2007) 1443
30. Gfesser G.A., Faghih R., Bennani Y.L., Curtis M.C., Esbenshade T.A., Hancock A.A., and Cowart M.D. Biorg. Med. Chem. Lett. 15 (2005) 2559
31. Cowart M.D., Gfesser G.A., Browman K.E., Faghih R., Miller T.R., Milicic I., Baranowski J.L., Krueger K.M., Witte D.G., Molesky A.L., Komater V.A., Buckley M.J., Diaz B.J., Gagne G.D., Zhou D., Deng X., Pan L., Roberts E.M., Diehl M.S., Wetter J.M., Marsh K.C., Fox G.B., Brioni J.D., Esbenshade T.A., and Hancock A.A. J. Biochem. Pharmacol. 73 (2007) 1243
32. Esbenshade T.A., Fox G.B., Krueger L.M., Miller T.R., Kang C.H., Denny L.I., et al. J. Pharmacol Exp. Ther. 313 (2005) 165
33. i (SEM) were typically <0.08.
34. Faghih R., Dwight W., Pan J.B., Fox G.B., Krueger K.M., Esbenshade T.A., McVey J.M., Marsh K., Bennani Y.L., and Hancock A.A. Bioorg. Med. Chem. Lett. 13 (2002) 1325
35. Potencies were compared by calculation of the ratio of potencies across series according to these formulae: frac(2 (R) - MePyr, 2 (S) - MePyr), frac(2 (R) - MePyr, Pyr), frac(2 (S) - MePyr, Pyr).